Document Detail

Secondary malignancy after imatinib therapy: Eight cases and review of the literature.
MedLine Citation:
PMID:  22329351     Owner:  NLM     Status:  Publisher    
Abstract: Chronic myeloid leukemia (CML) is a clonal stem cell disorder and imatinib is a small molecule inhibitor of Bcr Abl tyrosine kinase (TK) used in cases with CML. Immediate and short term side effects of this tyrosine kinase inhibitor (TKI) are well-known but the long term side effects have not yet been clearly identified. Although it has not been found an increased risk of secondary cancer in cases treated by imatinib in two large series, secondary malignancies have been reported in some cases using TKIs and this point is important in daily clinical practice for clinicians. Here we reported eight cases with neoplasias developing during imatinib therapy and reviewed the secondary malignant disorders during/after imatinib treatment.
Berna Bozkurt Duman; Semra Paydas; Umut Disel; Ayberk Besen; Emel Gurkan
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-14
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Richter's transformation in 16 of 149 Chinese patients with CLL.
Next Document:  Thalidomide consolidation improves progression-free survival in myeloma with normal but not upregula...